& Events
& Events

Inversago Pharma Awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference in Ottawa

MONTREAL (CANADA) – September 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada.

An initiative of BIOTECanada, the national industry association, coveted Gold Leaf Awards celebrate innovation and entrepreneurship within the Canadian biotech industry.

“On behalf of all of us at Inversago Pharma, I accept this prestigious award with honor and pride”, said François Ravenelle, PhD, Chief Executive Officer of Inversago Pharma. “More than a celebration, this award is a tribute to our team’s expertise and dedication to advancing the Company’s clinical programs, as we pursue our vision of developing a new class of drugs to bring relief to many patients worldwide”, concluded Dr. Ravenelle.

Inversago Pharma congratulates all nominees and award winners for making the Canadian biotech industry thrive and prosper.

For more information about 2022 Gold Leaf Awards categories and recipients, please visit:

About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. 


François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma inc.